Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Here’s Why

Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped down before the market opened on Monday . The stock had previously closed at $8.80, but opened at $8.26. Sysmex shares last traded at $8.54, with a volume of 2,860 shares traded.

Wall Street Analyst Weigh In

Separately, Citigroup downgraded Sysmex from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 16th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Sysmex presently has a consensus rating of “Hold”.

Sysmex Stock Performance

The business has a 50 day moving average price of $8.73 and a two-hundred day moving average price of $9.12. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.46 and a current ratio of 3.26. The company has a market cap of $5.39 billion, a P/E ratio of 22.53 and a beta of 1.10.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings results on Thursday, May 14th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). Sysmex had a return on equity of 7.23% and a net margin of 7.13%.The company had revenue of $877.92 million during the quarter, compared to analysts’ expectations of $862.45 million. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. On average, sell-side analysts anticipate that Sysmex Corporation ADR will post 0.37 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.